Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | F2 | P00734 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18481795 | 0.90 | ALDH1A1 (0.44) | TP53ALOX15ALDH1A1F2KDM4E | |
| SCHEMBL18471244 | 0.83 | FFAR1 (0.45) | FFAR1PDIA6 | |
| SCHEMBL15480487 | 0.83 | ALOX15 (0.50) | TP53ALOX15ALDH1A1F2KDM4E | |
| SCHEMBL15672741 | 0.82 | DRD2 (0.53) | ALDH1A1FFAR1KDM4EMAPT | |
| SCHEMBL13519133 | 0.81 | FFAR1 (0.39) | FFAR1PDIA6 | |
| SCHEMBL13518802 | 0.81 | FFAR1 (0.44) | FFAR1PDIA6 | |
| SCHEMBL18518617 | 0.81 | PDIA6 (0.46) | FFAR1PDIA6 | |
| SCHEMBL15782894 | 0.81 | DRD2 (0.52) | ALDH1A1 | |
| SCHEMBL13518964 | 0.80 | ALDH1A1 (0.46) | ALDH1A1FFAR1MAPTPDIA6 | |
| SCHEMBL13518803 | 0.80 | FFAR1 (0.46) | FFAR1PDIA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241521-A1 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | US | disclosed |
| US-9617251-B2 | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20170037040-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241521-A1 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR65, GPR52 | TP53 4528/4885ALOX15 744/4885ALDH1A1 1647/4885 |
| US-20170037040-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GPR119, GPR55, GPR65 | TP53 3987/4885ALOX15 790/4885ALDH1A1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.